TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 107 filers reported holding TARSUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.53 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $46,582,669 | +81.4% | 2,621,422 | +84.4% | 2.72% | +88.8% |
| Q2 2023 | $25,685,096 | +143657.2% | 1,421,422 | 0.0% | 1.44% | +22.3% |
| Q1 2023 | $17,867 | -29.8% | 1,421,422 | -18.1% | 1.18% | -30.9% |
| Q4 2022 | $25,456 | -99.9% | 1,736,422 | -11.9% | 1.70% | -27.8% |
| Q3 2022 | $33,751,000 | +23.3% | 1,971,422 | +5.1% | 2.36% | +14.0% |
| Q2 2022 | $27,375,000 | +18.3% | 1,875,000 | +36.3% | 2.07% | +16.5% |
| Q1 2022 | $23,144,000 | -26.7% | 1,375,982 | -1.9% | 1.78% | -5.4% |
| Q4 2021 | $31,575,000 | +1.4% | 1,403,331 | -2.9% | 1.88% | +48.5% |
| Q3 2021 | $31,136,000 | -29.0% | 1,444,831 | -4.6% | 1.26% | -15.2% |
| Q2 2021 | $43,884,000 | -20.6% | 1,514,269 | -11.7% | 1.49% | +21.1% |
| Q1 2021 | $55,251,000 | -21.0% | 1,714,269 | 0.0% | 1.23% | -26.1% |
| Q4 2020 | $69,965,000 | – | 1,714,269 | – | 1.66% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,034,158 | $25,569,366 | 3.81% |
| Vivo Capital, LLC | 2,262,200 | $28,435,854 | 1.97% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $22,469,214 | 1.63% |
| Cormorant Asset Management, LP | 1,421,422 | $17,867 | 1.18% |
| Sands Capital Ventures, LLC | 260,000 | $3,268,200 | 0.81% |
| RTW INVESTMENTS, LP | 2,548,125 | $32,029,931 | 0.67% |
| Perceptive Advisors | 1,296,416 | $16,295,949 | 0.48% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,156,032 | $14,531,322 | 0.32% |
| Ghost Tree Capital, LLC | 80,000 | $1,006,000 | 0.30% |
| TimesSquare Capital Management, LLC | 1,192,660 | $14,992 | 0.22% |